ABSTRACT

Conclusion:

In conclusion, to the best of our knowledge for the first time we found leukocyte platelet aggregate values increases in cancer patients of different stages and different tissue origin. To confirm the results we have achieved, and to demonstrate the potential impact of this information in estimation of thrombotic events in cancer patients more studies conducted in larger groups of patients are needed.

Results:

According to the results, monocyte platelet aggregates level of metastatic gastrointestinal tumors and operated tumors were found to be significantly higher compared to the control group (p: 0.05, 0.029, respectively. No significant difference was observed between the groups in the levels of thrombin-antithrombin III complex and neutrophil lymphocyte ratio.

When all groups were analyzed to assess the hypercoagulopathy, deep vein thrombosis frequency were identified as 22% (18 patients). The rate was 17% in operated tumors, and was 21% in metastatic lung tumors. The incidence of deep vein thrombosis in metastatic gastrointestinal tumors was found to be 35%. There was no significant difference between patients with and without deep vein thrombosis about age, monocyte platelet aggregates, granulocyte platelet aggregates, thrombin-antithrombin III complex and high-sensitivity C-reactive protein levels.

Material and Method:

In this study, we compared laboratory and clinical data of 28 metastatic gastrointestinal tumors, 33 metastatic lung tumors, 29 operated tumor patients, for a total of 90 patients with a control group consisting of 12 healthy volunteers followed at Namik Kemal University Oncology clinic in between 2013 -2014.

Objective:

The aim of our study was to determine the correlation between leukocyte platelet aggregates and thrombosis in patients with solid tumors who are susceptible to inflammation and thrombosis.